[ad_1]
Geneva, Switzerland
A New Formula for a Drug Against Prevents Postpartum Hemorrhage Could Save Thousands of Lives in Low- and Middle-Income Countries, According to a Study The World Health Organization (WHO) presented today
"For years, the medical community sought a drug that was not sensitive to the heat, which remained stable and effective at high temperature., Metin Gulmezoglu, WHO Coordinator of Maternal Health, said at a teleconference
"The results of the study could not be better, we have the opportunity to save tens of thousands of lives in the poorest countries. "19659003] The new drug is called" carbetocin – a stable temperature "and is formulated so that it can withstand temperatures of up to At 30 degrees It's about 100% centigrade and 75% relative humidity without spoiling for three years, a key aspect to be used in depressed areas without access to a refrigerator.
Traditionally, oxytocin has been used traditionally to combat postpartum haemorrhage, but this drug must be maintained at a stable temperature between 2 and 8 degrees Celsius both transported and stored, this which is eminently impossible in many developing countries.
"At high temperatures, oxytocin degrades, not because it has harmful effects, but it's just not effective." We've seen places where the dose necessary is inoculated three times as a method to balance the lack of efficiency, "says Gulmezoglu.
Each year, about 70,000 women die worldwide because of postpartum hemorrhage and after death. Based on the results of the study, the WHO estimates that in September, she will be able to recommend the use of "stable temperature carbetocin" as a method to avoid the risk of infant mortality. postpartum haemorrhage
The two molecules (oxytocin and carbetocin) are very similar, so they have very similar effects, only that the new drug is not sensitive to temperature changes.
"The idea is to recommend it as a preventive method, not as a treatment, because it has been shown that if the product is inoculated to the mother in the first minutes after childbirth, it is reduced to 40 to 50%
Currently, the WHO recommends inoculating all women with oxytocin after childbirth, something that will not change with the inclusion of the new remedy.
In addition, the expert recalled that the oxytocin has other very important uses during childbirth, such as induction
The study was based on a clinical trial with about 30,000 women, the largest of its kind, and in which 23 women participated: ten countries: Argentina, Egypt, India, Kenya, Nigeria, United Kingdom, Singapore, South Africa, Thailand and Uganda
For the time being, stable single-temperature carbetocin is permitted in clinical trials. ues, so the new L & # 39; s study was conducted in collaboration with MSD for Mothers, an initiative to find solutions to reduce mortality. Once the drug is regulated, the three entities will study how to implement it mbadively in countries where maternal mortality rates are high, given that the agreement they signed prior to the completion of the program was completed. The study included affordable distribution in 90 low-income countries. EFE
Source link
